• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer

Biolocity

Emory and Georgia Tech

  • Home
  • Funding
    • Application
  • Lab2Launch
  • Programs
    • Program History
  • Team
    • Oversight Committee
  • Success Stories
    • Funded Projects
    • Testimonials
  • Recent News
  • DRIVe
  • Legal Office Hours
  • B2MTalks
  • Events
    • Resources
You are here: Home / Commercialization / NephroDI Therapeutics Strikes Deal for Revolutionary Kidney Disease Treatment

June 23, 2023 by aheard6

NephroDI Therapeutics Strikes Deal for Revolutionary Kidney Disease Treatment

NephroDI

NephroDI Therapeutics, a Biolocity portfolio company, has made waves in the medical field with its recent agreement to develop a first-in-class treatment for a rare genetic disease affecting the kidneys. This development brings new hope to patients and their families who have been waiting for a targeted therapy to address congenital Nephrogenic Diabetes Insipidus (NDI). This collaboration is a testament to the power of scientific innovation and industry partnerships in driving advancements in healthcare and improving patient outcomes.

Learn more about this exciting news here.

Filed Under: Commercialization, News, Technology

Reader Interactions

Primary Sidebar

Footer

Connect with us

  • Email
  • Facebook
  • LinkedIn
  • Twitter

Keep In Touch

Register here to receive our emails on upcoming events and funding opportunities.

Copyright © 2023 · Executive Pro on Genesis Framework · WordPress · Log in